Cargando…
Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if patients are suspected of having drug-induced thrombocytopenia, the first step is to immediately discontin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165100/ https://www.ncbi.nlm.nih.gov/pubmed/37168994 http://dx.doi.org/10.3389/fphar.2023.1157437 |
_version_ | 1785038197517975552 |
---|---|
author | Li, Bi Liu, Ying Luo, Jiaqi Cai, Yun Chen, Mengli Wang, Tianlin |
author_facet | Li, Bi Liu, Ying Luo, Jiaqi Cai, Yun Chen, Mengli Wang, Tianlin |
author_sort | Li, Bi |
collection | PubMed |
description | One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if patients are suspected of having drug-induced thrombocytopenia, the first step is to immediately discontinue the offending drug. Even in patients with severe infections, the antibacterial drug may need to be changed or the antibacterial treatment may need to be discontinued because thrombocytopenia may have a more serious clinical prognosis. In addition, if the patient needs to continue antibacterial treatment after discharge, the lack of conditions for monitoring platelet levels may also pose hidden dangers to the patient. Contezolid is an orally administered oxazolidinone antibacterial agent approved by the National Medical Products Administration of China in 2021. We found that contezolid may have an improved safety profile with a significantly reduced potential for myelosuppression based on the results of our observational clinical study. In this article, we review the advantages of contezolid as a new oxazolidinone antibiotic and describe three typical clinical cases of patients who experienced drug-induced thrombocytopenia after using linezolid. The platelet levels of these different patients were all significantly improved to varying degrees after initiation of contezolid treatment. |
format | Online Article Text |
id | pubmed-10165100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101651002023-05-09 Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment Li, Bi Liu, Ying Luo, Jiaqi Cai, Yun Chen, Mengli Wang, Tianlin Front Pharmacol Pharmacology One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if patients are suspected of having drug-induced thrombocytopenia, the first step is to immediately discontinue the offending drug. Even in patients with severe infections, the antibacterial drug may need to be changed or the antibacterial treatment may need to be discontinued because thrombocytopenia may have a more serious clinical prognosis. In addition, if the patient needs to continue antibacterial treatment after discharge, the lack of conditions for monitoring platelet levels may also pose hidden dangers to the patient. Contezolid is an orally administered oxazolidinone antibacterial agent approved by the National Medical Products Administration of China in 2021. We found that contezolid may have an improved safety profile with a significantly reduced potential for myelosuppression based on the results of our observational clinical study. In this article, we review the advantages of contezolid as a new oxazolidinone antibiotic and describe three typical clinical cases of patients who experienced drug-induced thrombocytopenia after using linezolid. The platelet levels of these different patients were all significantly improved to varying degrees after initiation of contezolid treatment. Frontiers Media S.A. 2023-04-24 /pmc/articles/PMC10165100/ /pubmed/37168994 http://dx.doi.org/10.3389/fphar.2023.1157437 Text en Copyright © 2023 Li, Liu, Luo, Cai, Chen and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Bi Liu, Ying Luo, Jiaqi Cai, Yun Chen, Mengli Wang, Tianlin Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment |
title | Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment |
title_full | Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment |
title_fullStr | Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment |
title_full_unstemmed | Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment |
title_short | Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment |
title_sort | contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165100/ https://www.ncbi.nlm.nih.gov/pubmed/37168994 http://dx.doi.org/10.3389/fphar.2023.1157437 |
work_keys_str_mv | AT libi contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment AT liuying contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment AT luojiaqi contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment AT caiyun contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment AT chenmengli contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment AT wangtianlin contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment |